Paradigm Biopharmaceuticals Valuation

Is PAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PAR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PAR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PAR?

Key metric: As PAR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PAR. This is calculated by dividing PAR's market cap by their current book value.
What is PAR's PB Ratio?
PB Ratio	4x
Book	AU$23.81m
Market Cap	AU$98.10m

PAR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-1.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does PAR's PB Ratio compare to its peers?

The above table shows the PB ratio for PAR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	7.3x
CYP Cynata Therapeutics	5.4x	34.1%	AU$38.4m
BTG Beroni Group	8.7x	n/a	AU$75.9m
NOX Noxopharm	5.3x	n/a	AU$30.7m
DXB Dimerix	10x	n/a	AU$186.6m
PAR Paradigm Biopharmaceuticals	4x	8.8%	AU$98.1m

Price-To-Book vs Peers: PAR is good value based on its Price-To-Book Ratio (4x) compared to the peer average (6.9x).

Price to Book Ratio vs Industry

How does PAR's PB Ratio compare vs other companies in the AU Biotechs Industry?

1 Company	Price / Book	Estimated Growth	Market Cap
BNO Bionomics	0.3x	-36.0%	US$9.52m

No more companies available in this PB range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: PAR is expensive based on its Price-To-Book Ratio (4x) compared to the Australian Biotechs industry average (3.1x).

Price to Book Ratio vs Fair Ratio

What is PAR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PAR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PAR's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PAR forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	AU$0.27	AU$0.69 +155.6%	31.9%	AU$0.91	AU$0.47	n/a	2
Nov ’25	AU$0.20	AU$0.69 +236.6%	31.9%	AU$0.91	AU$0.47	n/a	2
Oct ’25	AU$0.20	AU$0.69 +253.8%	31.9%	AU$0.91	AU$0.47	n/a	2
May ’25	AU$0.28	AU$2.30 +705.3%	39.0%	AU$3.19	AU$1.40	n/a	2
Apr ’25	AU$0.34	AU$2.30 +565.2%	39.0%	AU$3.19	AU$1.40	n/a	2
Mar ’25	AU$0.34	AU$2.30 +585.1%	39.0%	AU$3.19	AU$1.40	n/a	2
Feb ’25	AU$0.32	AU$2.30 +628.6%	39.0%	AU$3.19	AU$1.40	n/a	2
Jan ’25	AU$0.42	AU$2.30 +440.0%	39.0%	AU$3.19	AU$1.40	n/a	2
Dec ’24	AU$0.40	AU$2.30 +481.0%	39.0%	AU$3.19	AU$1.40	n/a	2
Nov ’24	AU$0.41	AU$2.30 +453.0%	39.0%	AU$3.19	AU$1.40	AU$0.20	2
Oct ’24	AU$0.61	AU$2.70 +338.2%	18.4%	AU$3.19	AU$2.20	AU$0.20	2
Sep ’24	AU$0.66	AU$2.70 +308.3%	18.4%	AU$3.19	AU$2.20	AU$0.24	2
Aug ’24	AU$0.91	AU$2.70 +194.5%	18.4%	AU$3.19	AU$2.20	AU$0.26	2
Jul ’24	AU$0.99	AU$2.70 +172.2%	18.4%	AU$3.19	AU$2.20	AU$0.29	2
Jun ’24	AU$0.83	AU$2.70 +222.8%	18.4%	AU$3.19	AU$2.20	AU$0.25	2
May ’24	AU$1.00	AU$2.70 +169.5%	18.4%	AU$3.19	AU$2.20	AU$0.28	2
Apr ’24	AU$1.43	AU$2.70 +87.8%	18.4%	AU$3.19	AU$2.20	AU$0.34	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.13

6.1%

AVITA Medical

US$339.9m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.92

2.3%

25.0%

AVITA Medical

US$342.3m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.97

0.3%

19.6%